Vulvovaginal Candidiasis Clinical Trial
Official title:
Randomized Controlled Trial to Assess the Effectiveness of a Zinc-containing Vaginal Gel and Fluconazole on Treatment and Recurrence of Vulvovaginal Candidiasis.
Vaginitis is one of the most common gynecological problems in women. Candida albicans is responsible for more than 85% of vaginal fungal infections and reinfection after standard treatment is quite common. The aim of this study is to compare the effects of a zinc-containing vaginal gel and oral fluconazole on the treatment and recurrence of vulvovaginal candidiasis (VVC). The investigator's hypothesis is that zinc-containing vaginal gel may decrease the rate of reinfection after standard treatment with oral 150 mg fluconazole.
Randomized controlled trial will be conducted on 76 women with VVC, as confirmed by clinical and laboratory diagnosis. The participants will be allocated into two groups using blocked randomization method. In the control group participants will receive oral fluconazole treatment with a single dose of oral fluconazole (150 mg) while in the treatment group women will receive a single oral dose of fluconazole (150mg) followed by treatment with a zinc-containing vaginal gel (daily for 2 weeks and twice per week thereafter). Vaginal samples will be collected (vaginal swab and cervicovaginal lavage) at baseline and 4-8-12 weeks after starting treatment. In addition, the clinical signs and symptoms will be assessed before the intervention and follow-ups. Women will be asked to report any new symptoms of vaginal infections and will be asked to return for in-office evaluation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05012852 -
Evaluation of VagiVitalAC for Treatment of Candida Vulvovaginitis
|
N/A | |
| Completed |
NCT02150655 -
Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women
|
Phase 0 | |
| Completed |
NCT00755053 -
Comparative Efficacy of Ovule vs Tablet
|
Phase 3 | |
| Completed |
NCT02679456 -
Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis
|
Phase 2 | |
| Completed |
NCT02242695 -
Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis
|
Phase 4 | |
| Not yet recruiting |
NCT05079711 -
Comparative Performance of a Vaginal Yeast Test
|
||
| Completed |
NCT00895453 -
Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)
|
N/A | |
| Completed |
NCT05327192 -
VVC Sampling Study for Analysis Validation
|
||
| Completed |
NCT05399641 -
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
|
Phase 3 | |
| Completed |
NCT01806623 -
The Study Of Fluconazole For Vulvovaginal Candidiasis
|
Phase 3 | |
| Completed |
NCT05507333 -
Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis
|
N/A | |
| Completed |
NCT01144286 -
Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment
|
Phase 2 | |
| Completed |
NCT00353561 -
Diabetes Mellitus and Vulvovaginal Candidiasis
|
Phase 3 | |
| Recruiting |
NCT05908682 -
Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
|
||
| Completed |
NCT02203942 -
Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis
|
N/A | |
| Completed |
NCT01926028 -
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
|
Phase 1/Phase 2 | |
| Completed |
NCT00194324 -
Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina
|
Phase 4 | |
| Completed |
NCT02866227 -
TOL-463 Phase 2 Study for Vaginitis
|
Phase 2 | |
| Withdrawn |
NCT05031481 -
Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis.
|
Phase 2 | |
| Completed |
NCT03761628 -
Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis
|
N/A |